PTPRC and neoplasm: In addition, although surgical removal of the tumour mass is a curative therapy, in the cases of myxoma relapses, local administration of specific miR mimics/inhibitors (see Figure 6) to locally target c-kitpos/CD45 neg/CD31neg myxoma tumour initiating cells could be theoretically envisioned as a specific therapy for myxoma recurrences.